ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

  • Abstract Number: 0827 • ACR Convergence 2024

    Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme

    Paneez Khoury1, Jared Silver2, Gerhard Wolff3, Robert Price4, Rejina Verghis5, Emmeline Igboekwe2 and Michael E Wechsler6, 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2US Medical Affairs-Respiratory, GSK, Durham, 3Clinical Development-Respiratory, GSK, Collegeville, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Department of Medicine, National Jewish Health, Denver, CO

    Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…
  • Abstract Number: 2000 • ACR Convergence 2024

    Induction of Systemic Inflammatory Diseases with Dupilumab Therapy

    Jeanne Tisseau des Escotais1, Camille Taille2, Julie Merindol3, Matthieu Groh4, Perrine SMETS5, Amel Boudjemaa6, Alexandra Audemard7, Nabil Belfeki8, Philippe Bonniaud9, Chloe Comarmond10, Isabelle DELACROIX11, Charlotte Descours12, Lucile Grange13, Paul Legendre14, Nihal Martis15, Thomas Moulinet16, Béatrice Walls17, Laurent Chouchana1 and Benjamin Terrier18, 1Cochin, Paris, France, 2Bichat Hospital, Paris, France, 3Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, 4Foch, Suresnes, France, 5Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 6CHU créteil, Créteil, France, 7Tours, Tours, France, 8CH Melun, Melun, France, 9Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, 10Lariboisière University Hospital, Paris, France, 11CHI créteil, Créteil, France, 12CH Tours, Tours, France, 13CH Saint-Etienne, Saint-Etienne, France, 14Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 15CH Nice, Nice, France, 16CHRU de Nancy, Vandœuvre-lès-Nancy, France, 17Paris, Paris, France, 18Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
  • Abstract Number: 0828 • ACR Convergence 2024

    Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Benjamin Terrier5, Bernhard Hellmich6, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 6Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…
  • Abstract Number: 2479 • ACR Convergence 2024

    Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices

    Michael E Wechsler1, Anna Kovalszki2, Jared Silver3, Brian Stone4, Lior Seluk5, Lynn Huynh6, Wilson da Costa Junior6, Mingchen Ye6, Jeremiah Hwee7, Mei Sheng Duh6, William McCann4 and Amy G. Edgecomb8, 1Department of Medicine, National Jewish Health, Denver, CO, 2Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 3US Medical Affairs - Respiratory, GSK, Durham, 4Allergy Partners, Asheville, NC, 5Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, 6Analysis Group, Boston, MA, 7Value Evidence and Outcomes, GSK, Mississauga, Canada, 8US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 2482 • ACR Convergence 2024

    Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies

    Gerhard Wolff1, Michael E Wechsler2, Jared Silver3, Robert Price4, Rejina Verghis5, Peter Weller6, Peter Merkel7, Thomas Corbridge8 and Paneez Khoury9, 1Clinical Development-Respiratory, GSK, Collegeville, 2Department of Medicine, National Jewish Health, Denver, CO, 3US Medical Affairs-Respiratory, GSK, Durham, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8US Value Evidence and Outcomes, GSK, Durham, NC, 9National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
  • Abstract Number: L14 • ACR Convergence 2023

    Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

    Michael Wechsler1, Parameswaran Nair2, Benjamin Terrier3, Bastian Walz4, Arnaud Bourdin5, David Jayne6, David Jackson7, Florence Roufosse8, Lena Börjesson Sjö9, Ying Fan10, Maria Jison10, Christopher McCrae11, Sofia Necander9, Anat Shavit12, Claire Walton12 and Peter Merkel13, 1National Jewish Health, Denver, CO, 2McMaster University, Hamilton, ON, Canada, 3Cochin Hospital, Paris, France, 4University of Tübingen, Kirchheim-Teck, Germany, 5University of Montpellier, CHU Montpellier, INSERM, Montpellier, Montpellier, France, 6Addenbrooke's Hospital, Cambridge, United Kingdom, 7Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London,, London, United Kingdom, 8Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 9Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 10Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gaithersburg, MD, 11Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 12BioPharmaceutials Medical, AstraZeneca, Cambridge, United Kingdom, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…
  • Abstract Number: 0675 • ACR Convergence 2023

    Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond

    allyson egan1, Pasupathy Sivasothy2 and David Jayne3, 1Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, 2Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, 3University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
  • Abstract Number: 0676 • ACR Convergence 2023

    Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center

    Takashi Yamane1 and Akira Hashiramoto2, 1Kakogawa Central City Hospital, Kakogawa, Japan, 2Kobe University Graduate School of Health Sciences, Kobe, Japan

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
  • Abstract Number: 0677 • ACR Convergence 2023

    Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan

    SOKO KAWASHIMA1, Yoshinori Komagata1, Mitsumasa Kishimoto2 and Shinya Kaname1, 1Kyorin University School of Medicine, Tokyo, Japan, 2Kyorin University School of Medicine, Yokohoma, Japan

    Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
  • Abstract Number: 0678 • ACR Convergence 2023

    Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

    Adrien Cottu1, Matthieu Groh2, Charlène Desaintjean3, Sylvain Marchand-Adam4, Loic Guillevin5, Xavier Puéchal6, Estibaliz Lazaro7, Maxime Samson8, Camille Taillé9, Cécile-Audrey Durel10, Elisabeth Diot11, Sarah Nicolas11, Laurent Guilleminault12, Mikael Ebbo13, Pascal Cathébras14, Clairelyne Dupin9, Halil Yildiz15, Nabil Belfeki16, Gregory Pugnet17, Pierre Chauvin18, Stephane Jouneau19, François Lifermann20, Jean-Philippe Martellosio21, Vincent Cottin22 and Benjamin Terrier23, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 3Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, 4CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 5University Paris Descartes, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7Bordeaux Hospital University, Pessac, France, 8Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 9AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 10CHU Lyon, Lyon, France, 11Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 12Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 13Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, 14Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, 15Saint Luc Hospital, Bruxelles, Belgium, 16Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, 17CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 18Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, 19Amicus, Boca Raton, FL, 20Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 21Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, 22Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 23Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
  • Abstract Number: 0854 • ACR Convergence 2023

    Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis

    Martin Dutertre1, Gregory Pugnet2, Claire De Moreuil3, Bernard Bonnotte4, YGAL BENHAMOU5, Dominique Chauveau6, Elisabeth Diot7, Pierre Duffau8, Nicolas Limal9, Antoine Néel10, GEOFFREY URBANSKI11, Noémie Jourde-Chiche12, Nicolas MARTIN SILVA13, Francois Maurier14, Arsène Mekinian15, Nicolas Schleinitz16, Felix ackermann17, Anne-Laure Fauchais18, Antoine Froissart19, Thomas Le Gallou20, Yurdagul Uzunhan21, Jean-Francois Viallard22, Alice Berezne23, laurent chiche24, Bruno Crestani25, Guillaume Direz26, Cecile-Audrey DUREL27, Pascal Godmer28, Jean-Emmanuel Kahn29, Marc Lambert30, Mathilde de Menthon1, Thomas Quemeneur31, Jacques Cadranel1, Pierre Charles32, Antoine Dossier1, Loic Guillevin33, Xavier Puéchal34 and Benjamin Terrier35, 1AP-HP, Paris, France, 2CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 3CHU de Brest, Brest, France, 4Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 5rouen university hospital, Rouen, France, 6Hôpital Le Tripode, Bordeaux, France, 7Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 8CHU Bordeaux, Bordeaux, France, 9AP-HP, Créteil, France, 10CHU de Nantes, Nantes, France, 11CHU Angers, Angers, France, 12AP-HM, Marseille, France, 13CHU Caen, Caen, France, 14Hôpitaux privés de Metz, Vaux / Frankreich, France, 15Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, 16Aix Marseille university, AP-HM, Marseille, France, 17Hôpital Foch, Suresnes, France, 18Dupuytren Hospital, Limoges, France, 19CHI Créteil, Créteil, France, 20CHU Rennes, Rennes, France, 21AP-HP, Bobigny, France, 22CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, 23CH Annecy, Annecy, France, 24Hopital Europeen, Marseille, France, 25Hopital Bichat, Paris University, Paris, France, 26CH Le Mans, Le Mans, France, 27Hospices Civils de Lyon, Lyon, France, 28CH Bretagne Atlantique, Vannes, France, 29AP-HP, Suresnes Cedex, France, 30CHRU Lille, Lille, France, 31CH Valenciennes, Valenciennes, France, 32Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 33University Paris Descartes, Paris, France, 34National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 35Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
  • Abstract Number: 0856 • ACR Convergence 2023

    Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

    Berengere Molina1, Roberto Padoan2, Maria Letizia Urban3, Pavel Novikov4, Marco Caminati5, Camille Taillé6, Antoine Néel7, Laurence Bouillet8, Paolo Fraticelli9, Nicolas Schleinitz10, Christine Christides11, Laura Moi12, Bertrand Godeau13, Ann Knight14, Jan Walter Schroeder15, Sylvain Marchand-Adam16, Helder Gil17, Vincent Cottin18, Cécile-Audrey Durel19, Elena Gelain20, Boris Lerais21, Marc Ruivard22, Matthieu Groh23, Maxime Samson24, Luca Moroni25, Jens Thiel26, Anna Kernder27, Jan Willem Cohen Tervaert28, Giulia Costanzo29, Marco Folci30, Sonia Rizzello31, Pascal Cohen32, Giacomo Emmi33 and Benjamin Terrier34, 1Cochin Hospital, Paris, France, 2Department of Medicine DIMED, University of Padova, Padova, Italy, 3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 4Sechenov First Moscow State Medical University, Moscow, Russia, 5University of Verona, Verona, Italy, 6AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 7CHU Nantes, Nantes, France, 8Internal medicine department, Grenoble University Hospital, Grenoble, France, 9University Hospital Ospedali Riuniti, Ancona, Italy, 10Aix Marseille university, AP-HM, Marseille, France, 11Avignon Hospital, Avignon, France, 12Valais Hospital, Sion, Switzerland, 13CHU Henri Mondor, Créteil, France, 14Uppsala University, Uppsala, Sweden, 15ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 16CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 17CHU Besancon, Besançon, France, 18Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 19CHU Lyon, Lyon, France, 20Meyer Children's Hospital, Florence, Italy, 21Brest University Hospital, Brest, France, 22CHU Clermont Ferrand, Clermont Ferrand, France, 23National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 24Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 25San Raffaele Scientific Institute, Milan, Italy, 26University Hospital Freiburg, Freiburg, Germany, 27Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, 28University of Alberta, Edmonton, AB, Canada, 29University of Cagliari, Monserrato, Italy, 30Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, 31Careggi University Hospital, Florence, Italy, 32CHU Cochin, Paris, France, 33University of Florence, Florence, Italy, 34Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…
  • Abstract Number: 1546 • ACR Convergence 2023

    Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

    Ricardo Blanco1, Iñigo Rúa-Figueroa2, Roser Solans3, Maria C Cid4, Marina Blanco5, Ismael Garcia Moguel6, Francisco Perez Grimaldi7, Ana Noblejas8, Moises Labrador3, Cristian Domingo9, Georgina espigol10, Fernando Sanchez Toril11, Francisco Ortiz-Sanjuán12, Ebymar Arismendi13 and Jose María Alvaro-Gracias14, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 3Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Hospital Clinic Barcelona, Barcelona, Spain, 5Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, 6Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, 7Pneumology Department, H. University of Jerez, Cádiz, Spain, 8Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, 9Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, 10Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, 11Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, 12Hospital Universitario y Politécnico La Fe, Valencia, Spain, 13Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, 14Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
  • Abstract Number: 1547 • ACR Convergence 2023

    Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing small-to-medium vessel vasculitis with a relapsing-remitting course involving prodromal (various allergic reactions), eosinophilic (infiltration into…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology